Adults With Moderate to Severe Asthma
Launched by ASTRAZENECA · Mar 18, 2008
Trial Information
Current as of June 13, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female aged 12 or over who have asthma
- • Ability to properly use an electronic diary
- • Able and willing to nebulize for up to 20 minutes every morning and evening
- Exclusion Criteria:
- • Hospitalised at least one once or required emergency treatment due to asthma in the previous 6 months
- • Planned hospitalisation during the study
- • pregnant women or women planning to become pregnant
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Bertil Andersson
Study Director
AstraZeneca
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials